MA61123B1 - Composition à base de lipides pour l'administration par voie orale d'antagonistes des récepteurs b2 de la bradykinine - Google Patents
Composition à base de lipides pour l'administration par voie orale d'antagonistes des récepteurs b2 de la bradykinineInfo
- Publication number
- MA61123B1 MA61123B1 MA61123A MA61123A MA61123B1 MA 61123 B1 MA61123 B1 MA 61123B1 MA 61123 A MA61123 A MA 61123A MA 61123 A MA61123 A MA 61123A MA 61123 B1 MA61123 B1 MA 61123B1
- Authority
- MA
- Morocco
- Prior art keywords
- bradykinin
- oral administration
- methyl
- lipid
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des compositions pharmaceutiques pour administration orale comprenant un antagoniste du récepteur de la bradykinine (BK) B2 ayant une structure chimique selon la formule 1, ou un sel ou un solvate de celui-ci, où R est le deutérium ou l'hydrogène : Formule (1), telle que (S)-N-(1-deutéro-1-(3-chloro-5-fluoro-2-((2-méthyl-4-(1-méthyl-1H-1,2,4-triazol-5-yl)quinoléine-8-yloxy)méthyl)phényl)éthyl)-2-(difluorométhoxy)acétamide. Les compositions comprennent l'antagoniste du récepteur BK B2 sous une forme dissoute dans un véhicule liquide comprenant du monocaprylate de propylèneglycol, de l'huile de ricin polyoxyl et du propylèneglycol. L'invention concerne en outre des utilisations thérapeutiques des compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189990 | 2021-08-05 | ||
| EP22760986.4A EP4203919B1 (fr) | 2021-08-05 | 2022-08-05 | Composition à base de lipides pour l'administration par voie orale d'antagonistes des récepteurs b2 de la bradykinine |
| PCT/EP2022/072049 WO2023012322A1 (fr) | 2021-08-05 | 2022-08-05 | Composition à base de lipide pour l'administration orale d'antagonistes du récepteur b2 de la bradykinine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61123B1 true MA61123B1 (fr) | 2024-06-28 |
Family
ID=77226756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61123A MA61123B1 (fr) | 2021-08-05 | 2022-08-05 | Composition à base de lipides pour l'administration par voie orale d'antagonistes des récepteurs b2 de la bradykinine |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240350418A1 (fr) |
| EP (1) | EP4203919B1 (fr) |
| JP (1) | JP2024528195A (fr) |
| KR (1) | KR20240039185A (fr) |
| CN (1) | CN118076342B (fr) |
| AU (1) | AU2022323749A1 (fr) |
| BR (1) | BR112024002215A2 (fr) |
| CA (1) | CA3227476A1 (fr) |
| CO (1) | CO2024001171A2 (fr) |
| DK (1) | DK4203919T3 (fr) |
| ES (1) | ES2978563T3 (fr) |
| FI (1) | FI4203919T3 (fr) |
| HR (1) | HRP20240525T1 (fr) |
| HU (1) | HUE066306T2 (fr) |
| IL (1) | IL310321A (fr) |
| LT (1) | LT4203919T (fr) |
| MA (1) | MA61123B1 (fr) |
| MX (1) | MX2024001711A (fr) |
| PL (1) | PL4203919T3 (fr) |
| PT (1) | PT4203919T (fr) |
| RS (1) | RS65427B1 (fr) |
| SI (1) | SI4203919T1 (fr) |
| SM (1) | SMT202400157T1 (fr) |
| WO (1) | WO2023012322A1 (fr) |
| ZA (1) | ZA202401504B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| CA2364178C (fr) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine |
| WO2008055146A2 (fr) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations d'inhibiteurs d'enzymes phospholipase |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| WO2014159637A1 (fr) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Méthodes de traitement de l'œdème de quincke induit par le récepteur de la bradykinine du type b2 |
| AR113839A1 (es) | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2022
- 2022-08-05 MA MA61123A patent/MA61123B1/fr unknown
- 2022-08-05 IL IL310321A patent/IL310321A/en unknown
- 2022-08-05 KR KR1020247007280A patent/KR20240039185A/ko active Pending
- 2022-08-05 CN CN202280067108.5A patent/CN118076342B/zh active Active
- 2022-08-05 PT PT227609864T patent/PT4203919T/pt unknown
- 2022-08-05 HU HUE22760986A patent/HUE066306T2/hu unknown
- 2022-08-05 BR BR112024002215A patent/BR112024002215A2/pt unknown
- 2022-08-05 ES ES22760986T patent/ES2978563T3/es active Active
- 2022-08-05 FI FIEP22760986.4T patent/FI4203919T3/fi active
- 2022-08-05 AU AU2022323749A patent/AU2022323749A1/en active Pending
- 2022-08-05 SM SM20240157T patent/SMT202400157T1/it unknown
- 2022-08-05 SI SI202230031T patent/SI4203919T1/sl unknown
- 2022-08-05 CA CA3227476A patent/CA3227476A1/fr active Pending
- 2022-08-05 RS RS20240456A patent/RS65427B1/sr unknown
- 2022-08-05 EP EP22760986.4A patent/EP4203919B1/fr active Active
- 2022-08-05 PL PL22760986.4T patent/PL4203919T3/pl unknown
- 2022-08-05 LT LTEPPCT/EP2022/072049T patent/LT4203919T/lt unknown
- 2022-08-05 DK DK22760986.4T patent/DK4203919T3/da active
- 2022-08-05 MX MX2024001711A patent/MX2024001711A/es unknown
- 2022-08-05 WO PCT/EP2022/072049 patent/WO2023012322A1/fr not_active Ceased
- 2022-08-05 HR HRP20240525TT patent/HRP20240525T1/hr unknown
- 2022-08-05 US US18/681,298 patent/US20240350418A1/en active Pending
- 2022-08-05 JP JP2024506610A patent/JP2024528195A/ja active Pending
-
2024
- 2024-02-05 CO CONC2024/0001171A patent/CO2024001171A2/es unknown
- 2024-02-20 ZA ZA2024/01504A patent/ZA202401504B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2978563T3 (es) | 2024-09-16 |
| PL4203919T3 (pl) | 2024-06-10 |
| FI4203919T3 (fi) | 2024-05-03 |
| KR20240039185A (ko) | 2024-03-26 |
| SI4203919T1 (sl) | 2024-08-30 |
| RS65427B1 (sr) | 2024-05-31 |
| US20240350418A1 (en) | 2024-10-24 |
| PT4203919T (pt) | 2024-04-23 |
| EP4203919A1 (fr) | 2023-07-05 |
| EP4203919B1 (fr) | 2024-01-31 |
| CN118076342B (zh) | 2025-08-05 |
| HUE066306T2 (hu) | 2024-07-28 |
| ZA202401504B (en) | 2025-06-25 |
| CA3227476A1 (fr) | 2023-02-09 |
| CO2024001171A2 (es) | 2024-05-20 |
| CN118076342A (zh) | 2024-05-24 |
| JP2024528195A (ja) | 2024-07-26 |
| AU2022323749A1 (en) | 2024-02-08 |
| DK4203919T3 (da) | 2024-04-29 |
| BR112024002215A2 (pt) | 2024-04-30 |
| SMT202400157T1 (it) | 2024-05-14 |
| IL310321A (en) | 2024-03-01 |
| WO2023012322A1 (fr) | 2023-02-09 |
| MX2024001711A (es) | 2024-03-05 |
| TW202320774A (zh) | 2023-06-01 |
| LT4203919T (lt) | 2024-05-10 |
| HRP20240525T1 (hr) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025138849A (ja) | プリナブリン組成物及びその使用 | |
| EP0170139B1 (fr) | Composition fongicide | |
| US8906951B1 (en) | Use of NK-1 receptor antagonists in pruritus | |
| WO2006081327A2 (fr) | Petites molecules limitant la croissance fongique | |
| CN1516581A (zh) | 含具有氨基磺酰基的活性化合物(cox-2抑制剂)、聚乙二醇和清除游离基的抗氧化物的口服传递的药用组合物 | |
| JP2010280733A (ja) | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 | |
| US20110053903A1 (en) | Pharmaceutical compositions based on azetidine derivatives | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| MA34553B1 (fr) | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué | |
| WO1997013509A1 (fr) | Inhibiteur de permeation vasculaire | |
| JP2020536965A (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| JP2019151645A (ja) | 局所投与用薬学的組成物 | |
| MA34313B1 (fr) | Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan | |
| FR2784899B1 (fr) | Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire | |
| MA61123B1 (fr) | Composition à base de lipides pour l'administration par voie orale d'antagonistes des récepteurs b2 de la bradykinine | |
| JP5021887B2 (ja) | アゼチジン誘導体に基づく医薬組成物 | |
| KR101413846B1 (ko) | ４－［５－（４－메칠페닐）－３－（트리플루오로메칠）피라졸－１－일］벤젠술폰아미드 화합물 함유 액상 조성물 | |
| KR20040106422A (ko) | 간암 및 다른 암 질병 치료용 에포틸론 유도체 | |
| JP2005200419A (ja) | 癌治療法 | |
| MA69209B1 (fr) | Composition solide comprenant des antagonistes solubilisés de récepteur b2 de la bradykinine | |
| AU683447B2 (en) | Medicament for treating or preventing cerebrovascular diseases | |
| JP2023014328A (ja) | 外用医薬組成物 | |
| Fukuhara et al. | The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo | |
| Tripodi et al. | Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein |